Q-POC Handheld Laboratory
Q-POC is a portable diagnostics device.
Q-POC is a solar-powered or wind-up handheld tool designed to diagnose, manage, monitor, and track infections and drug resistance. DNA-based diagnostics can be performed at point-of-care in 10-20 minutes with Q-POC. The device also includes GPS-enabled epidemiological surveillance. Q-POC is currently in a prototype stage and is expected to be commercialized soon.
Single use test cartridges are being developed for Warfarin dosage, malaria and drug resistance, hospital acquired infections, and tumor profiling.
Device: 1000 USD, cartridges: 5-20 USD
Goal 3: Good health and well-being
Healthcare workers, pharmacists, nurses, doctors
Unknown, as the product has not been commercialized yet.
N/A, product commercialization expected 2019
The Q-POC is a portable, battery-operated diagnostics device that can process blood, urine, sputum, tissue, and swabs and delivers results in 10-20 minutes.
DNA testing with the Q-POC involves the steps of sample prep and DNA extraction, amplification, and detection. QuantuMDx has developed a Warfarin sensitivity test, HPV, STI and TB tests, but MRSA/C.DIFF, Gonorrhea/Chlamydia, and BRAF/MSI tests are planned in the future as well.
Results are displayed on a touchscreen and can be stored on the device, sent to a printer, or transferred to a computer or the Cloud via USB or WiFi.
Globally distributed Q-POC devices will also geotag and anonymize pathogen data and send to the cloud for real-time disease and drug resistance monitoring.
Provided by the manufacturer
QuantuMDx seeks Q-POC can provide personalized medicine, be portable, provide a quick diagnosis, allow for geotagging an creating a network of data.
99% sensitivity and specificity to molecular results
Dunning, L., Kroon, M., Hsiao, N., and Myer, L., 2017, Field Evaluation of HIV Point-of-Care Testing for Early Infant Diagnosis in Cape Town, South Africa, PloS One, 12(12), p. e0189226.
Vu, C., Chan, J., Todaro, M., Skafidas, S., and Kwan, P., 2015, Point-of-Care Molecular Diagnostic Devices: an Overview, Pharmacogenomics, 16(12), pp. 1399-1409.
Dorman, S., 2015, Advances in the Diagnosis of Tuberculosis: Current Status and Future Prospects, The International Journal of Tuberculosis and Lung Disease, 19(5), pp. 504-516.
Basha, I., Ho, E., 2017, Towards Multiplex Molecular Diagnosis—A Review of Microfluidic Genomics Technologies, Micromachines, 8(9), p. 266.
QuantumDx plans to obtain CE marking for all of the Q-POC tests in the short term and then pursue a 510(k) submission with the US Food and Drug Administration.
Clinical trials planned in South Africa
In context photographs (0)
You can use the form below to contribute a photo of this product.
In context files & documents (0)
Feedback from users, customers & distributors
Please let us know your experience in using this product through comments below.